Publicaciones destacadas

• Association of her2dx with pathological complete response and survival outcomes in her2-positive breast cancer

  Prat Aparicio; Aleix;

  Referencia:

  2023.

• Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021

  H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;

  M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.

  Referencia:

  2021.

• Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

  Pascual, T; Fernandez-Martinez, A; Tanioka, M; Dieci, MV; Pernas, S;

  (...)

  Pare, L; Galvan, P; Carey, LA; Perou, C; Prat, A.

  Ver listado completo de autores

  Referencia:

  Clinical Cancer Research 2021.

• Correlative Biomarker Analysis of Intrinsic Subtypes

  Prat Aparicio; Aleix;

  Referencia:

  2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Prat A; Guarneri V; Paré L; Griguolo G; Pascual T;

  (...)

  Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P.

  Ver listado completo de autores

  Referencia:

  Lancet Oncology 2020.

• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M;

  (...)

  Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A .

  Ver listado completo de autores

  Referencia:

  Breast Cancer Research 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

  (...)

  Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

  Ver listado completo de autores

  Referencia:

  Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Prat A; Saura C; Pascual T; Hernando C; Muñoz M;

  (...)

  López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J .

  Ver listado completo de autores

  Referencia:

  Lancet Oncology 2020.